Iran Thrown a Nuclear-Medicine Lifeline Ahead of Vienna Meeting
(Bloomberg) -- The world's atomic watchdog said it's ready to meet shortages of nuclear medicines in Iran created by the re-imposition of U.S. sanctions, as top diplomats gather to salvage a 2015 deal with Tehran.
The International Atomic Energy Agency is “willing to help” meet Iran's nuclear therapy and medicine needs, Director General Yukiya Amano told reporters Monday in Vienna. The Islamic Republic has struggled to obtain some humanitarian goods as suppliers worry over contravening U.S. penalties, prompting Switzerland and the European Union to open new trade channels.
Trump's Sanctions Are Proving a Bitter Pill for Iran's Sick
IAEA inspectors have repeatedly confirmed that Iran's sticking to the landmark deal signed three years ago, which capped nuclear activities for sanctions relief. President Donald Trump's decision to abandon the accord in May forced the remaining powers -- China, France, Germany, Russia and the U.K. -- to take new measures to ensure its survival. Their so-called Joint Commission convenes Wednesday in the Austrian capital.
In addition to its monitoring activities, the IAEA helps countries around the world to develop medicine used for the diagnosis and treatment of cancer.
Leading up to this week's meeting, American officials had been ratcheting up pressure by threatening new sanctions and advocating for more aggressive inspections. Countries providing technical cooperation to Iran under IAEA auspices were warned they could run afoul of U.S. sanctions. Washington's efforts, however, have struggled to gain traction among international officials.
“Iran is implementing its nuclear-related commitments,” Amano said. “The agency continues to verify the non-diversion of nuclear material.”
To contact the reporter on this story: Jonathan Tirone in Vienna at jtirone@bloomberg.net
To contact the editors responsible for this story: Reed Landberg at landberg@bloomberg.net, Mark Williams, Stuart Biggs
©2019 Bloomberg L.P.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
-
Navigating Energy Crossroads: S Jaishankar's Call For Diversified Supply Chains At G20 Ministerial Meeting
As geopolitical fault lines continue to test maritime trade routes and commodity flows, Jaishankar's message remains pertinent: true economic resilience requires open markets, protected transit lines, and a genuine commitment to multilateral cooperation rather than coercion.
-
Indians Are Travelling, But Not Every Journey Is A Holiday | The Week In Whys
Pilgrims, patients and working women are the real travellers, and the system hasn't quite caught up with them.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
